Multi-cell lineage culturing media. Simplified workflow & unparalleled clinical accuracy
Hematopathology diagnostic services at the highest level of accuracy, quality, and service
We do this by capturing insights from our cancer diagnostics clinical laboratory, selecting our best technologies to commercialize into products, and selling them through a network of global distribution partners.
1 in 4 blood cancer patients is misclassified. We get it right from the start through cutting-edge technology and unparalleled expertise.
Learn More
We develop proprietary technologies to meet the diagnostic needs of personalized medicine with faster turn around times.
Learn More
A dedicated team of hematopathologists with decades of clinical expertise. Always up to date on the latest WHO & NCCN guidelines.
Learn MorePrecipio’s culture is one of care. The company exists to battle a problem that affects hundreds of thousands of patients, and their families, each year. Every patient that is impacted by the work we do, is treated with the same care we would treat our own family.
Precipio’s platform delivers superior diagnostic accuracy through specialized expertise and cutting edge technology. We are a laboratory focused on delivering superior hematology diagnostic services to physicians and their patients to ensure they receive accurate results.
The Latest at Precipio
NEW HAVEN, CT, (June 12th, 2026) – Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting [...]
Read More
NEW HAVEN, CT, Globenewswire – (June 11, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: [...]
Read More
Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth [...]
Read MoreStay up to date on the latest news and information.
Sign up for our newsletter
CaseVu
